Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 997 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Coming together for Zynlonta July 2, 2021 Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery February 12, 2020 Science Surgery: ‘How are children’s cancers different from adult’s cancers?’ September 28, 2020 Hopes for the future of cancer research – a video from... April 16, 2023 Load more HOT NEWS FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... New on NCI’s Websites for March 2019 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February
